Compare Adaptive Biotechnologies Corp (ADPT) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Booz Allen Hamilton Holding Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Booz Allen Hamilton Holding Corporation trades at $63 (market cap $7.59B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 2.3× Adaptive Biotechnologies Corp's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.73% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BAH | |
|---|---|---|
Market Cap | $3.33B | $7.59B |
Sector | Health | Industrials |
52-Week High | $22.37 | $115.95 |
52-Week Low | $10.24 | $59.71 |
Enterprise Value | $3.19B | $10.99B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Booz Allen Hamilton (BAH) trades at $63.31, up 1.38% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $12.0B in 2025 and impressive profitability metrics including 80.17% ROE. Recent developments include strategic AI partnerships with OpenAI and acquisitions to strengthen defense technology capabilities, though the stock faces near-term pressure from civil business weakness.
BAH presents a compelling value opportunity with attractive valuation multiples (P/E 9.03, P/S 0.68) and analyst consensus target of $87.25 representing 38% upside. However, investors face risks from FY27 transition expectations, civil segment pressures, and technical resistance near $64-65 levels. The company's government-focused model provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
